AllianceBernstein
SRNE

AllianceBernstein’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

AllianceBernstein’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-279,400
Closed -$248K – 3270
2022
Q4 		$248K Hold
279,400
– – ﹤0.01% 2933
2022
Q3 		$439K Sell
279,400
-40,700
-13% -$92.3K ﹤0.01% 2712
2022
Q2 		$643K Hold
320,100
– – ﹤0.01% 2566
2022
Q1 		$746K Buy
320,100
+900
+0.3% +$2.81K ﹤0.01% 2524
2021
Q4 		$1.48M Sell
319,200
-100,000
-24% -$621K ﹤0.01% 2296
2021
Q3 		$3.2M Buy
419,200
+93,400
+29% +$792K ﹤0.01% 1866
2021
Q2 		$3.16M Hold
325,800
– – ﹤0.01% 1904
2021
Q1 		$2.69M Buy
325,800
+9,100
+3% +$96.1K ﹤0.01% 1908
2020
Q4 		$2.16M Buy
316,700
+2,300
+0.7% +$18.5K ﹤0.01% 1932
2020
Q3 		$3.51M Buy
314,400
+55,900
+22% +$512K ﹤0.01% 1545
2020
Q2 		$1.62M Sell
258,500
-414,900
-62% -$1.59M ﹤0.01% 1959
2020
Q1 		$1.24M Buy
673,400
+400,000
+146% +$1.15M ﹤0.01% 1939
2019
Q4 		$924K Buy
273,400
+100,000
+58% +$238K ﹤0.01% 2312
2019
Q3 		$371K Buy
173,400
+17,700
+11% +$41.3K ﹤0.01% 2703
2019
Q2 		$416K Buy
155,700
+9,700
+7% +$34.9K ﹤0.01% 2696
2019
Q1 		$694K Buy
146,000
+25,600
+21% +$67.2K ﹤0.01% 2407
2018
Q4 		$289K Buy
120,400
+36,300
+43% +$119K ﹤0.01% 2752
2018
Q3 		$370K Buy
84,100
+37,200
+79% +$206K ﹤0.01% 2756
2018
Q2 		$338K Buy
+46,900
New +$319K ﹤0.01% 2768
2017
Q2 		– Sell
-38,800
Closed -$153K – 3194
2017
Q1 		$153K Hold
38,800
– – ﹤0.01% 2896
2016
Q4 		$190K Buy
38,800
+2,900
+8% +$17.4K ﹤0.01% 2902
2016
Q3 		$278K Buy
35,900
+4,349
+14% +$29.3K ﹤0.01% 2726
2016
Q2 		$177K Buy
31,551
+6,651
+27% +$42.5K ﹤0.01% 2824
2016
Q1 		$134K Sell
24,900
-5,100
-17% -$29.6K ﹤0.01% 2789
2015
Q4 		$261K Buy
30,000
+3,900
+15% +$32.9K ﹤0.01% 2667
2015
Q3 		$219K Buy
26,100
+9,900
+61% +$158K ﹤0.01% 2748
2015
Q2 		$285K Buy
+16,200
New +$208K ﹤0.01% 2771

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

AllianceBernstein's SRNE Position: Q1 2023 in Review

AllianceBernstein sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 279,400 shares — an estimated $248K sold.

AllianceBernstein first reported a position in SRNE in Q2 2015 and held it in 27 quarters. The position peaked at $3.51M in Q3 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • AllianceBernstein reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • AllianceBernstein sold 279,400 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $248K.
  • AllianceBernstein first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 27 quarters.
  • AllianceBernstein's Sorrento Therapeutics, Inc. position peaked at $3.51M in Q3 2020.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on AllianceBernstein's 13F filing for Q1 2023, filed 15 May 2023.